Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic

Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic

Bibliographic Details
Main Authors:	Ashis K. Das, Eunice Chang, Caleb Paydar, Michael S. Broder, Kate K. Orroth, Myriam Cordey
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-07-01
Series:	Dermatology and Therapy
Online Access:	https://doi.org/10.1007/s13555-023-00984-2

Similar Items

Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
by: Ashis K. Das, et al.
Published: (2023-07-01)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
by: Forchhammer S, et al.
Published: (2015-09-01)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
by: Palfreeman, A, et al.
Published: (2013)

Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis
by: Yu. L. Korsakova, et al.
Published: (2018-07-01)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
by: Haddad A, et al.
Published: (2023-10-01)

THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
by: Palfreeman AC, et al.
Published: (2013-03-01)

Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)

[Translated article] Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis
by: P. Garbayo Salmons, et al.
Published: (2022-05-01)

Clinical potential of apremilast in the treatment of psoriatic arthritis
by: Cauli A, et al.
Published: (2014-06-01)

Redefining Disease Severity with Special Area Involvement and Reflecting on Treatment Patterns in a Real-World Psoriasis Population
by: Mary E. Horner, et al.
Published: (2024-01-01)

Apremilast for lithium-associated psoriasis
by: Joohyung Youh, et al.
Published: (2022-01-01)

Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01)

Acrodermatitis continua of Hallopeau with psoriatic arthritis treated with biologics and apremilast
by: Shohei Igari, et al.
Published: (2023-09-01)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
by: Husni ME, et al.
Published: (2022-06-01)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
by: Hagberg KW, et al.
Published: (2020-02-01)

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
by: Murage MJ, et al.
Published: (2018-08-01)

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
by: Constanze Jonak, et al.
Published: (2023-02-01)

Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
by: Thomas G. Salopek
Published: (2017-08-01)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
by: Wen-Ming Wang, et al.
Published: (2020-05-01)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
by: Caleb Jeon, BS, et al.
Published: (2017-11-01)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
by: Mease, PJ, et al.
Published: (2020)

APREMILAST: AN UPDATE ON ITS EFFICACY AND SAFETY DURING LONG-TERM TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2018-11-01)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

GENETICS OF PSORIASIS AND PSORIATIC ARTHRITIS
by: V. Ibba, et al.
Published: (2011-09-01)

EPIDEMIOLOGY OF PSORIASIS AND PSORIATIC ARTHRITIS
by: M.A. Cimmino
Published: (2011-09-01)

Genetics of psoriasis and psoriatic arthritis
by: Chandran Vinod
Published: (2010-01-01)

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population
by: Chang Xu, et al.
Published: (2022-05-01)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
by: Dmitry A. Verbenko, et al.
Published: (2020-12-01)

Apremilast in psoriasis and beyond: Big hopes on a small molecule
by: T P Afra, et al.
Published: (2019-01-01)

Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom
by: Anthony Bewley, et al.
Published: (2018-01-01)

Dramatic response of cutaneous, nail, and joint symptoms of psoriasis to apremilast
by: Meghana Bathina, et al.
Published: (2019-01-01)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
by: Rajagopalan M, et al.
Published: (2021-08-01)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Cardiovascular risk factors in psoriatic disease: psoriasis psoriatic arthritis
by: Nuria Barbarroja, et al.
Published: (2019-10-01)

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
by: Muhammad K. Nisar
Published: (2019-01-01)

IMMUNE PATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS
by: S. V. Smirnova, et al.
Published: (2014-08-01)